The Supreme Court and Federal Circuit’s recent decisions invalidating patents under section 101 of the Patent Act as patent-ineligible subject matter have affected patent portfolios across all industries, from biotechnology patents and the development of personalized medicine to computer and software patents. These recent decisions have made it essential to reassess your company’s patent strategy to ensure protection of your inventions and enable future partnering and marketing success.
Please join our speakers as they review the rapidly changing legal landscape for biotechnology and software patents. Topics will include:
- Background on section 101 of the Patent Act and its recent emergence as an area of interest for the Supreme Court and Federal Circuit
- Recent developments in section 101 cases law, including the Supreme Court’s Prometheus and Myriad decisions (biotechnology industry), the Court’s Bilski decision, and the Federal Circuit’s decision in CLS Bank (computer and software industries)
- Strategic patent claim analysis in view of these decisions